Insider · CIK 0001686223
Khoso Baluch
Files at PCSA (Processa Pharmaceuticals, Inc.), LGVN (Longeveron Inc.). First filing Dec 4, 2024, latest Apr 1, 2026.
In brief
Khoso Baluch files SEC Form 4 as director at PCSA (Processa Pharmaceuticals, Inc.), and also at LGVN (Longeveron Inc.). Since Dec 4, 2024, Khoso Baluch has reported 1 open-market buy worth $5,752 and 1 open-market sell worth $2,588, the latest filed on Apr 1, 2026.
A track record needs three past buys with six months of prices behind them; Khoso Baluch has 0, so none is measured yet.
The newest scored trade: bought $5,752 of PCSA on Mar 31, 2026, filed Apr 1, 2026, scored 48 (moderate). In the last 12 months: 1 buy worth $5,752 and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
PCSA: Processa Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
LGVN: Longeveron Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | Processa Pharmaceuticals, Inc. | $5,752 2,269 shares | +4052% | +36% from low-79% from high | |
| 15Weak | LGVNsell Longeveron Inc. | $2,588 1,250 shares | -5% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 27, 2024 | LGVN Longeveron Inc. | 1,250 0.01% of outstanding | $2,575 | Nov 27, 2024 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 26, 2026 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +33,500 | $0.00 | $0 | 38,749 | Jul 28, 2026 |
| Jun 26, 2026 | PCSA Processa Pharmaceuticals, Inc. | MOption exercise Common Stock | +203 | - | - | 2,528 | Jun 30, 2026 |
| Jun 26, 2026 | PCSA Processa Pharmaceuticals, Inc. | MOption exercise Restricted Stockderivative | -203 | $0.00 | $0 | 5,249 | Jun 30, 2026 |
| Mar 31, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,269 | $2.54 | $5,752 | 2,325 | Apr 1, 2026 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +100,000 | $0.00 | $0 | 100,000 | Oct 3, 2025 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Oct 3, 2025 |
| Sep 3, 2024 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stockderivative | +31,206 | $0.00 | $0 | 36,275 | Sep 18, 2025 |
| Aug 11, 2025 | LGVN Longeveron Inc. | POpen-market purchase Class A Common Stock | +11,766 | - | - | 52,516 | Aug 13, 2025 |
| Aug 11, 2025 | LGVN Longeveron Inc. | POpen-market purchase Warrant (right to buy)derivative | +29,415 | - | - | 29,415 | Aug 13, 2025 |
| Jul 24, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stockderivative | +175,299 | $0.00 | $0 | 206,505 | Jul 28, 2025 |
| Jul 15, 2025 | LGVN Longeveron Inc. | AGrant or award Class A Common Stock | +17,000 | $0.00 | $0 | 40,750 | Jul 17, 2025 |
| Dec 2, 2024 | LGVN Longeveron Inc. | SOpen-market sale Class A Common Stock | -1,250 | $2.07 | $2,588 | 23,750 | Dec 4, 2024 |
| Dec 21, 2023 | LGVN Longeveron Inc. | AGrant or award Stock Option (Right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Dec 26, 2023 |
Questions about Khoso Baluch
Answered from the filings on this page, as of the latest one.
Is Khoso Baluch buying or selling?
In the last 12 months Khoso Baluch reported 1 open-market buy worth $5,752 and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $5,752 of PCSA on Mar 31, 2026. Grants, option exercises and tax withholding are not counted.
How did Khoso Baluch's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Khoso Baluch has 0.
Where does Khoso Baluch file Form 4?
Khoso Baluch has filed Form 4 at PCSA (Processa Pharmaceuticals, Inc.); LGVN (Longeveron Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.